About this item:

1,239 Views | 693 Downloads

Author Notes:

Email Address: Joanna B. Goldberg : joanna.goldberg@emory.edu

Conceived and designed the experiments: DAM JMS PPG SKBC AD JBG. Performed the experiments: DAM JMS PPG SKBC AD.

Analyzed the data: DAM PPG SKBC AD JBG. Contributed reagents/materials/analysis tools: DMW TJI.

Wrote the paper: DAM JMS PPG SKBC AD JBG.

We are thankful to Dr. Donald Woods (University of Calgary) for kindly supplying the plasmid p1C3. We also thank Dr. Paul Brett (University of South Alabama) for supplying the Pp-PS-W antibody.

We are grateful to Aloka Bandara and Anna Champions (Virginia Tech) for technical assistance.

We gratefully acknowledge Dr. Sanford Feldman (University of Virginia), Dr. Ana Patricia Garcia (Division of Pathology, Yerkes National Primates Research Center-Emory University) for preparing the histopathology report.

We also would like to thank the Immunology Core at Emory + Children’s Pediatric Research Center.

Competing Interests: The authors have declared that no competing interests exist.

Subjects:

Research Funding:

This work was supported by National Institutes of Health (NIH) Grants R21-AI073923 to JBG and R21-AI081130 to TJI. JMS, PG, and SKBC were supported in part on an NIH Infectious Disease Training Grant (T32-AI007046) awarded to the University of Virginia.

Recombinant Salmonella Expressing Burkholderia mallei LPS O Antigen Provides Protection in a Murine Model of Melioidosis and Glanders.

Tools:

Journal Title:

PLoS ONE

Volume:

Volume 10, Number 7

Publisher:

, Pages e0132032-e0132032

Type of Work:

Article | Final Publisher PDF

Abstract:

Burkholderia pseudomallei and Burkholderia mallei are the etiologic agents of melioidosis and glanders, respectively. These bacteria are highly infectious via the respiratory route and can cause severe and often fatal diseases in humans and animals. Both species are considered potential agents of biological warfare; they are classified as category B priority pathogens. Currently there are no human or veterinary vaccines available against these pathogens. Consequently efforts are directed towards the development of an efficacious and safe vaccine. Lipopolysaccharide (LPS) is an immunodominant antigen and potent stimulator of host immune responses. B. mallei express LPS that is structurally similar to that expressed by B. pseudomallei, suggesting the possibility of constructing a single protective vaccine against melioidosis and glanders. Previous studies of others have shown that antibodies against B. mallei or B. pseudomallei LPS partially protect mice against subsequent lethal virulent Burkholderia challenge. In this study, we evaluated the protective efficacy of recombinant Salmonella enterica serovar Typhimurium SL3261 expressing B. mallei O antigen against lethal intranasal infection with Burkholderia thailandensis, a surrogate for biothreat Burkholderia spp. in a murine model that mimics melioidosis and glanders. All vaccine-immunized mice developed a specific antibody response to B. mallei and B. pseudomallei O antigen and to B. thailandensis and were significantly protected against challenge with a lethal dose of B. thailandensis. These results suggest that live-attenuated SL3261 expressing B. mallei O antigen is a promising platform for developing a safe and effective vaccine.

Copyright information:

This is an open access article, free of all copyright.

This is an Open Access article distributed under the terms of the Creative Commons Universal : Public Domain Dedication License ( http://creativecommons.org/publicdomain/zero/1.0/), which permits distribution of derivative works, distribution, public display, and publicly performance, making multiple copies, provided the original work is properly cited.

Creative Commons License

Export to EndNote